{"name":"Rexahn Pharmaceuticals, Inc.","slug":"rexahn-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"RX-0201 plus Gemcitabine","genericName":"RX-0201 plus Gemcitabine","slug":"rx-0201-plus-gemcitabine","indication":"Other","status":"phase_2"},{"name":"RX-10100","genericName":"RX-10100","slug":"rx-10100","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"RX-0201 plus Gemcitabine","genericName":"RX-0201 plus Gemcitabine","slug":"rx-0201-plus-gemcitabine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RX-10100","genericName":"RX-10100","slug":"rx-10100","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPRGdKaXRfVFdEcDVnTGdQRFd4NEVRejk5eTNwNXltMFJBZWlmTTlORk1tWWxPd3VmOW9rSDQ3OEE4dGU0M2wtTlF3cmNVS0RnY0o1WmpGNjl0RTltZDJiVmRVOXBjaVcyTDUwYXN2NmxnUDhUVTVsZzZESFB0SXkzX1c4cVVyZXN4ZURDT3FFaE1JV2sxcjc3S01fTll0Z1JSay0xZnBNd1l4ZTlwX2JUVGhTR1MydXl4UjNreklqYTB2bG9BZlZKQWRpbUlKamZ3REltc3ZFS3JpN01zTlFOT2NxNFFYdk01WTFBVGZ1UjltZWRPYktCOGdtVU9OZENMRERCXzZwOGNHaHI2U1ZQV1pwYkx4Q1hEWDFrZGQwZDdrT3FiUXpNckdhWm1PMnUzdWpsV3ktZzNUeWNC?oc=5","date":"2025-12-10","type":"pipeline","source":"PR Newswire UK","summary":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight - PR Newswire UK","headline":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQdzFpSE1yTHo4bG5Td1VOUTVFeHhxRjZzSTJSb2xDQjBsWjVWMUdSVDJQWERwTXozQTFuakpSTjFwQnVQUHllRmFmeC00UlhXdUtyVVpYRlhiOGFvSzNzSUxoUjROekVzejlsdmQ3Rmt4eTBhWjdQVmtJWkdQOF9JYVY1N1QtRVppZkNZaWFyZU1oNnZRRHQ2YVNQTV9ST1FnRkNjaUs5UEhLUHhw?oc=5","date":"2025-07-01","type":"pipeline","source":"Fierce Biotech","summary":"Processa hands cancer candidate back to Opus Genetics after deciding milestone out of reach - Fierce Biotech","headline":"Processa hands cancer candidate back to Opus Genetics after deciding milestone out of reach","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQaFdwb0t1NlhNcW40ZnpENlYyRjJuVXA4aUNkWFBKRlJkQXJ4NzBsenBJVUpXVUdzWnJZRUc1TlVWRTJGekVHb0xUZHo2N0JKZDZNUFpTWjJhNmdVQTBVWEh6aEdlVEJGdVFhSjZxS1lKU0NLelg5bk5xSzN4NEJyalBVcmwyaDM3aUltTUJRTEQzekRVelJtOHcyZHpmLVlfaW1ZTGNXX0s5OHViem5NNjlKMUJiUFdVVGllQWt0X2taaG0z?oc=5","date":"2025-03-20","type":"patent","source":"Investing.com","summary":"Opus Genetics enhances shareholder rights, sues for patent infringement - Investing.com","headline":"Opus Genetics enhances shareholder rights, sues for patent infringement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOUjREcTNvVFpXY0tZTU1wdkxlWjdCYkhOSjAwOEIxMmtGU1hSVHFWOUl3clVXOFowMlhCelBBR1ZmZEtzSXJ4NjdxMTQ4NnVGUzhxQkhZQlpOR0ZlNUNpRFNKOFY5YWdRUlRVUGl1eUtmWlcyVWx1T09jMVAxNVhqT1hxUlhDVlo1LVZXRzJGWEhHZTFCOFJoaGFZOVBWUjFaZ0dLVnBxUS1UT2FJOGxLMFR6SzEtN1laUlR4WkFpSVpnVnU3WkxLTzZhWVh3SmJfNC0tYVhlNkRQNmxHU053NGVscS1SZjlKZEUtSVhzRUEtbU1ueGttMkFJaUxwb2gyQkoyYVN1RjI5UTg?oc=5","date":"2022-04-22","type":"pipeline","source":"GlobeNewswire","summary":"Global Targeted Drug Delivery Market to Surpass US$ 22,704 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswire","headline":"Global Targeted Drug Delivery Market to Surpass US$ 22,704 Million by 2030, Says Coherent Market Insights (CMI)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOTl9tbzR4UGJEa0tUU1czM2thTHVCZmNTb3NLWVpLbThUU0FGcXhpaW54NFZ0SDFjZ3o4UEhjVUZzVmNQLTQ5N080UjdnXzBFM2ZzVW9jd3BpemlkSm55WW95Q2tWUkhlRWpzMnpNMHBVUGJLWGVvY1NKc2NIaXVvODNCeXExWmpYcU1Kdk9LZkpRTGFaeUE?oc=5","date":"2020-11-05","type":"pipeline","source":"Yahoo Finance","summary":"Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP - Yahoo Finance","headline":"Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNaElEbEk0bnlMdzhMZ1VrQkNyclJ0MUs0U0RkRVg2ZDN5dEVralc5VUdQVm0xNmp3eDUyQUNFbnR1TE9IT3RxOXdHYlNFcFNNN2owdG84ZjQyM1VTbzg0UlM2NUhhWjVKME5sXzI1blpoY19BTEdPcHp5cnhzLUp2NTNBNUdrV0tJT1paRVJmTGJTZW9mZkRZdzQwYmI0dGNBSWZVN1RfYVVrVnRSTkw5SEtUcjVxQmU0Wk40UFpManF6c09F?oc=5","date":"2020-06-26","type":"pipeline","source":"ChartMill","summary":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Rexahn Pharmaceuticals, Inc. - ChartMill","headline":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Rexahn Pharmaceuticals, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPVmN6QTZfdmplem9EejdxLVd6Qzl5NlRGbWhaVnJQaWYzcWNYRFgzZDR4NkFVWUlrcnJCMzlVMkR2RFlPX2lGTXVhdEF2MDBUQ01DRElOQ0dOajNmdWROZFNKZjdCQXJPWkx6eVpISE9qVXUwa1N6amU4OHdGbGkyZGFXWXFxcTJR?oc=5","date":"2018-02-08","type":"deal","source":"Contract Pharma","summary":"Rexahn & Haichang Enter Collaboration - Contract Pharma","headline":"Rexahn & Haichang Enter Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE03NUlxejJZc3laaVJmQjhDX1JfdUhlbzh5V1JuMDFPY0lpaE1TUHNMR1g5d1dIcVQyeXBYY2x5QWhtUmxFVzlISUtnaW5MZUdwUXJ3STNONFZpUVpndkFra3FaenZHODhRRmllNlA3dmRoZjFWbE1uQ3VtdEc?oc=5","date":"2011-02-14","type":"pipeline","source":"CBS News","summary":"The 10 Strangest Names for Drug Companies - CBS News","headline":"The 10 Strangest Names for Drug Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNN05qYS1WRlNtMnd4OUVYQTVzMWtsM1dCY3l2UFdVZEdaTWJ0ZFFZb2FwOHRXR2lGLXMwd3dGcG5SNzc5OXNCdkJwRm5rVkx6aTY2bmwyaWNrQVRQUmJ3SjdSSHJ2UU52WHRuZUlBLVkwM3Zfc1huU3hGbUQwbVk4Und1ZENxeksyQ0hHQ19Fczc5TjdxUHpHSHNQYW8wTG41N3JXRThIbGpJUWNLSlh5NW5OSDVuczBQWXpkV25IdjJUajh6alphTWdZaDVfbXRxTkEtQVBqQzJpYUk1MDBBMUc4Sm1BNjg?oc=5","date":"2010-05-13","type":"trial","source":"Proactive Investors","summary":"Rexahn Pharma to Initiate Zoraxel Phase IIb trial for treating erectile dysfunction - Proactive Investors","headline":"Rexahn Pharma to Initiate Zoraxel Phase IIb trial for treating erectile dysfunction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOWWpvb2ZiTV83MHVaQThIaHQ0cWZGT082eWFNZVRodXNjaXZlY0xhdlU3a0RJSmN3NUlzbGRCSjVJQlJEeEM0M1N2dWlaZ2x5ZUxhNW9tV1RuMkdyYi0zc3Y2LUVPTS1hU1NCUGE1R1loWlE5WFhWczFfcngzRG11VUItOF9vZFZSQkpndE5yY2hQWXBCLVlmYWhCTFJOeWlhZkxMeWFFZ1NCNWlfZTJIdExkRTMyYUV3bEN2OW01YzdzbnhiaFdjR1d0NWFUQQ?oc=5","date":"2010-03-11","type":"patent","source":"proactiveinvestors.com","summary":"Rexahn Pharma secures Japanese patent for anti-cancer drug Archexin - proactiveinvestors.com","headline":"Rexahn Pharma secures Japanese patent for anti-cancer drug Archexin","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}